Overcoming poor adherence is a major hurdle to managing atopic dermatitis

Strowd, Lindsay C.; Feldman, Steven R.

doi:10.1111/bjd.18455

Cited by 6 publications

(7 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A multidisciplinary approach including early attention to atopic and psychiatric comorbidities is needed to overcome the painful, itching and stigmatising flare‐ups as well as their impact on quality of life, aiming for a fast and effective management of exacerbations as well as long‐term disease control. 4 , 16 , 17 , 23 , 24 …”

Section: Challenges and Unmet Needs In The Management Of Ad As A Rati...mentioning

confidence: 99%

“…A multidisciplinary approach including early attention to atopic and psychiatric comorbidities is needed to overcome the painful, itching and stigmatising flare-ups as well as their impact on quality of life, aiming for a fast and effective management of exacerbations as well as longterm disease control. 4,16,17,23,24 F I G U R E 1 More than a skin disease-atopic and non-atopic comorbidities in AD. integrating quality assurance and describing coordination of care.…”

Section: Challenges and Unmet Needs In The Management Of Ad As A Rati...mentioning

confidence: 99%

“…Hence, in addition to guidelines and consensus reports, ICPs for all involved stakeholders are warranted in consideration of the complexity and variability of the disease and with a particular focus on the large number of patients with milder forms of AD. A multidisciplinary approach including early attention to atopic and psychiatric comorbidities is needed to overcome the painful, itching and stigmatising flare‐ups as well as their impact on quality of life, aiming for a fast and effective management of exacerbations as well as long‐term disease control 4,16,17,23,24 …”

Section: Challenges and Unmet Needs In The Management Of Ad As A Rati...mentioning

confidence: 99%

See 2 more Smart Citations

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs

Zuberbier

Beck

Bedbrook³

et al. 2023

Clinical & Translational All

View full text Add to dashboard Cite

Background GA 2 LEN‐ADCARE is a branch of the largest multidisciplinary network of research centres and clinical care in allergy and asthma, GA 2 LEN, focussing on the field of atopic dermatitis (AD). AD is a chronic inflammatory skin disease with high burden and many comorbidities requiring different levels of treatment. The need for aligned information from all involved healthcare providers led to the discussion of an integrated care pathway (ICP) plan for AD patient care involving all stakeholders and considering the complexity and variability of the disease, with a particular focus placed on the large number of patients with milder forms of AD. Methods The GA 2 LEN ADCARE network and all stakeholders, abbreviated the AD‐ICPs working group, were involved in the discussion and preparation of the AD‐ICPs during a series of subgroup workshops and meetings in years 2020 and 2021. Results Here we discuss the unmet needs in AD, the methodology for devising an AD‐ICP and the ICP action plan. Conclusion The GA 2 LEN ADCARE network has outlined the unmet needs in AD and provided an action plan for devising AD‐ICPs, considering the complexity and variability of the disease.

show abstract

Section: Challenges and Unmet Needs In The Management Of Ad As A Rati...mentioning

confidence: 99%

Section: Challenges and Unmet Needs In The Management Of Ad As A Rati...mentioning

confidence: 99%

Section: Challenges and Unmet Needs In The Management Of Ad As A Rati...mentioning

confidence: 99%

See 1 more Smart Citation

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs

Zuberbier

Beck

Bedbrook³

et al. 2023

Clinical & Translational All

View full text Add to dashboard Cite

show abstract

“…[6][7][8] A multidisciplinary concept of management and care is needed, considering atopic and non-atopic comorbidities, aiming for the detection and identification of atopic status, the elimination of exacerbating factors, a fast and effective management of exacerbations as well as long-term disease control (Figure 1A,B). [17][18][19][20][21] Accordingly, approaches have been developed in appreciation of the complex interplay among biological, psychological, behavioural, and dietary factors and the wide range of knowledge, skills, and support that patients and families require to effectively manage and cope with this condition. 6 In consideration of the complex pathophysiology and heterogenous clinical phenotype of AD, more individualised preventative and therapeutic strategies are desirable.…”

Section: Introductionmentioning

confidence: 99%

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative

Zuberbier,

Abdul Latiff,

Aggelidis

et al. 2023

Clinical & Translational All

View full text Add to dashboard Cite

IntroductionThe integrated care pathways for atopic dermatitis (AD‐ICPs) aim to bridge the gap between existing AD treatment evidence‐based guidelines and expert opinion based on daily practice by offering a structured multidisciplinary plan for patient management of AD. ICPs have the potential to enhance guideline recommendations by combining interventions and aspects from different guidelines, integrating quality assurance, and describing co‐ordination of care. Most importantly, patients can enter the ICPs at any level depending on AD severity, resources available in their country, and economic factors such as differences in insurance reimbursement systems.MethodsThe GA2LEN ADCARE network and partners as well as all stakeholders, abbreviated as the AD‐ICPs working group, were involved in the discussion and preparation of the AD ICPs during a series of subgroup workshops and meetings in years 2020 and 2021, after which the document was circulated within all GAL2EN ADCARE centres.ResultsThe AD‐ICPs outline the diagnostic procedures, possible co‐morbidities, different available treatment options including differential approaches for the pediatric population, and the role of the pharmacists and other stakeholders, as well as remaining unmet needs in the management of AD.ConclusionThe AD‐ICPs provide a multidisciplinary plan for improved diagnosis, treatment, and patient feedback in AD management, as well as addressing critical unmet needs, including improved access to care, training specialists, implementation of educational programs, assessment on the impact of climate change, and fostering a personalised treatment approach. By focusing on these key areas, the initiative aims to pave the way for a brighter future in the management of AD.

show abstract

“…An important reason for low TCS adherence are concerns about side effects and negative consequences of TCS use, so called ‘corticophobia’ [ 8 , 9 ]. Strowd et al [ 10 ] described the major hurdle of overcoming these adherence barriers, underlining the importance of clear patient education and counseling.…”

Section: Introductionmentioning

confidence: 99%

Reducing corticosteroid phobia in pharmacy staff and parents of children with atopic dermatitis

et al. 2021

View full text Add to dashboard Cite

Background Besides physicians, pharmacy staff has an important role to inform patients on appropriate medication use. However, they might also experience corticophobia themselves, affecting patient counseling and subsequently patient’s disease management. Objective Implementation of an intervention for pharmacy staff to improve knowledge and stimulate positive perceptions towards TCS use, in order to reduce corticophobia in pharmacy staff and parents of young AD patients. Setting Nine community pharmacies in the Netherlands. Method We developed an intervention consisting of education of pharmacy staff followed by counseling of parents. The intervention was implemented in pharmacies and intervention effectiveness was studied using a pre-post design with an intervention period of 3 months. At baseline and follow-up (3 months), pharmacy staff and parents completed a questionnaire. Main outcome measure Corticophobia, both beliefs and worries, measured with the TOPICOP questionnaire. Higher scores indicate a more negative attitude. Result Baseline and follow-up data were available for 19 pharmacy staff members and 48 parents who attended a counseling session in the pharmacy. In both groups there was as decrease in negative beliefs and worries towards TCS (p < 0.05). Mean total TOPICOP scores decreased from 42 to 35% and from 33 to 25% for parents and pharmacy staff respectively. Conclusion Our results show the prevalence of corticophobia among parents. Education of pharmacy staff and targeted patient counseling seems to be effective in reducing corticophobia.

show abstract

Overcoming poor adherence is a major hurdle to managing atopic dermatitis

Abstract: Linked Article: Choi et al. Br J Dermatol 2020; 182:1017–1025.

Cited by 6 publications

References 4 publications

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative

Reducing corticosteroid phobia in pharmacy staff and parents of children with atopic dermatitis

Contact Info

Product

Resources

About

Overcoming poor adherence is a major hurdle to managing atopic dermatitis

Abstract: Linked Article: Choi et al. Br J Dermatol 2020; 182:1017–1025.

Cited by 6 publications

References 4 publications

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs

Developing integrated care pathways for atopic dermatitis—Challenges and unmet needs

A concept for integrated care pathways for atopic dermatitis—A GA2LEN ADCARE initiative

Reducing corticosteroid phobia in pharmacy staff and parents of children with atopic dermatitis

Contact Info

Product

Resources

About

A concept for integrated care pathways for atopic dermatitis—A GA²LEN ADCARE initiative